Genetic PCR Solutions™ laboratories have confirmed that their GPS™ MPXV dtec-qPCR assay is valid for the detection of both clade I and clade II variants of the Mpox virus.

Genetic PCR Solutions™ laboratories, a registered trademark of Genetic Analysis Strategies S.L., were the first laboratory in the world to develop a commercial kit for the detection of the Mpox virus (MPXV) when the outbreak of Mpox emerged in May 2022. The reference laboratory Instituto de Salud Carlos III (ISCIII) evaluated clinical samples, demonstrating greater sensitivity compared to tests from other multinational companies.

This same virus, responsible for the current outbreak of Mpox in the central-eastern African region, was declared a public health emergency of international concern (PHEIC) on Wednesday, August 14, 2024.

Since then the R&D team at GPS™ has conducted a thorough study of all the genomes of this virus that have been found to date worldwide, with sequences deposited in databases (a total of 7,378 Mpox virus sequences as of August 22, 2024). It has been determined that the GPS™ MPXV dtec-qPCR kit is valid for all strains of the virus currently circulating, including the new emerging variant 1b in the Kivu region (Congo Basin, Central Africa).

In addition, the laboratory is developing a new PCR test that will allow for the determination of whether the sample specifically contains this new, more virulent variant in the same assay.

Visit geneticpcr.com